Clinical Trial: Barrett's Esophagus - 315 - 3 Way Cross-Over

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Multicenter, Double-blind, Three-way Crossover Intraesophageal and Intragastric pH Study of Three Esomeprazole Treatment Regimens in Documented Barrett's Esophagus Patie

Brief Summary: This study looks the intragastric and intraesophageal pH in patients with documented Barrett's esophagus whilst taking esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.

Detailed Summary:
Sponsor: AstraZeneca

Current Primary Outcome: To compare the total percent time during the 24-hour monitoring period that gastric pH is above 4.0 at steady state in patients when taking: esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily. [ Time Frame: pH measured on Day 5 ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Compare total percent time distal esophageal pH is above 4.0 at steady state for each treatment period. [ Time Frame: pH measured ]

Original Secondary Outcome: Same as current

Information By: AstraZeneca

Dates:
Date Received: March 11, 2008
Date Started: March 2002
Date Completion:
Last Updated: January 24, 2011
Last Verified: January 2011